Sunitinib malate

• Background :

  Sunitinib malate is a receptor tyrosine kinase inhibitor. It has been shown to target VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, c-KIT, FLT3, CSF-1R, Flk-1, and RET.

• Description :

  VEGFR, PDGFR kinase inhibitor

• Product Name Alternative :

  N-[2- (Diethylamino) ethyl]-5-[ (Z) - (5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S) -2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

• UNSPSC :

  41116105

• Type :

  Inhibitor

• Source :

  Synthetic

• Field of Research :

  Cell Signaling | Cancer | Apoptosis | Cardiovascular System | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

• Purity :

  ≥99%

• Weight :

  0.005

• Format :

  Yellow solid

• Solubility :

  Soluble in DMSO (40 mg/ml)

• Molecular Formula :

  C22H27FN4O2

• Molecular Weight :

  398.5

• Precautions :

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations :

  1. Hersey P., et al. (2009) Annals of Oncology: ESMO. 20 Suppl 6: vi35–40.

• CAS Number :

  557795-19-4